Scientists from the Center for Genetic Engineering and Biotechnology (CIGB) together with researchers from the Cuban health system have been developing for a decade a promising vaccine candidate HeberSaVax to guarantee the survival of patients with liver cancer or hepatocarcinoma, a pathology that annually causes more than half a million deaths worldwide.
The three provincial hospitals in Holguín will have, once installed, five medical oxygen plants that began entering the territory last week as part of a donation from the People's Republic of China.
The research takes place within the collaboration framework between the Center for Molecular Immunology of Cuba and the Roswell Park Center of the United States.
The province of Holguín, although with fewer positive cases of dengue and COVID-19 reported in the last week, maintains a worrying epidemiological situation, for which it is necessary to continue with prevention measures and increase control and supervision in the communities as the main alternative to avoid getting sick.